Eliem Therapeutics (ELYM) News Today

Eliem Therapeutics (NASDAQ:ELYM) Trading 4.6% Higher

Eliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) was the recipient of a significant increase in short interest during the month of July. As of July 15th, there was short interest totalling 742,200 shares, an increase of 98.8% from the June 30th total of 373,300 shares. Based on an average trading volume of 307,600 shares, the days-to-cover ratio is presently 2.4 days. Approximately 1.3% of the shares of the company are short sold.

Eliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) EVP Valerie Morisset sold 42,377 shares of the firm's stock in a transaction on Monday, July 15th. The shares were sold at an average price of $7.01, for a total value of $297,062.77. Following the completion of the sale, the executive vice president now owns 252,306 shares of the company's stock, valued at $1,768,665.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Eliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) was the recipient of a large increase in short interest in the month of June. As of June 30th, there was short interest totalling 373,300 shares, an increase of 552.6% from the June 15th total of 57,200 shares. Currently, 0.8% of the shares of the company are sold short. Based on an average trading volume of 918,600 shares, the days-to-cover ratio is presently 0.4 days.

Eliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) Director Ra Capital Management, L.P. acquired 13,008,546 shares of Eliem Therapeutics stock in a transaction on Thursday, June 27th. The shares were bought at an average price of $3.84 per share, for a total transaction of $49,952,816.64. Following the completion of the purchase, the director now directly owns 23,521,757 shares in the company, valued at $90,323,546.88. The purchase was disclosed in a legal filing with the SEC, which is available through this link.

Eliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) was the target of a significant decline in short interest during the month of May. As of May 31st, there was short interest totalling 59,900 shares, a decline of 53.5% from the May 15th total of 128,800 shares. Based on an average daily trading volume, of 863,600 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.3% of the shares of the company are sold short.

Eliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) saw a significant growth in short interest in the month of May. As of May 15th, there was short interest totalling 128,800 shares, a growth of 127.2% from the April 30th total of 56,700 shares. Based on an average trading volume of 850,300 shares, the short-interest ratio is presently 0.2 days. Approximately 0.7% of the shares of the company are sold short.

Eliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) was the target of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 601,100 shares, an increase of 4,453.8% from the March 31st total of 13,200 shares. Currently, 3.3% of the company's stock are short sold. Based on an average trading volume of 665,800 shares, the short-interest ratio is currently 0.9 days.

BML Capital Management LLC boosted its position in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report) by 12.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,180,000 shares of the comp

Eliem Therapeutics (NASDAQ:ELYM) Shares Up 0.5%

Silverarc Capital Management LLC trimmed its holdings in Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report) by 75.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 121,110 shares of the company's stock after selling

Eliem Therapeutics (NASDAQ:ELYM) Trading Up 3.5%